SARS-CoV-2 Archives | Be Korea-savvy

Home / Posts tagged SARS-CoV-2

Understanding the Evolution of SARS-CoV-2 Could Be the Key to Treating It, According to Researchers at the UCSF QBI Coronavirus Research Group (QCRG)

SAN FRANCISCO, Oct. 25 (Korea Bizwire) — Researchers at the UCSF QBI Coronavirus Research Group (QCRG) have uncovered how the SARS-CoV-2 variants of concern (VOC) differ in their ability to manipulate human cells on a molecular level during infection. They have discovered variant specific differences in viral RNA and protein levels, including viral proteins N, Orf6, and [...]

Hyris’ New T-Cell Test is Finally Available to EU Countries to Easily Map Patients’ Cellular Immunity to SARS-CoV-2

LONDON, Aug. 5 (Korea Bizwire) — As the pandemic crisis has entered a new phase, it is a common belief among the scientific community that COVID-19 is here to stay, maybe for a long time. Many scientists expect the virus that causes COVID-19 to become endemic. According to a 2021 Nature’s poll, administered to more [...]

A New T-Cell Activation Assay Based on Hyris qPCR Technology Marks a Disruptive Approach for the Detection of SARS-CoV-2 Specific Cellular Immunity

LONDON, June 15 (Korea Bizwire) — With over 460 million global cases thus far, 6 million of which have resulted in death, the COVID-19 pandemic from SARS-CoV-2 proved to be a dire health crisis on a global scale. In this concerning scenario, the unprecedented effort by the international scientific community is even more remarkable and led [...]

Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants

WALTHAM, Mass., Oct. 19 (Korea Bizwire) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new in vitro data demonstrating retained neutralizing activity of its monoclonal antibody (mAb), ADG20, against a diverse panel of circulating SARS-CoV-2 variants, including [...]

Hyris Brings to Market Worldwide a New Test That Can Quickly Detect the Body’s T-Cell Immune Response to SARS-CoV-2, Thanks to a Partnership with Singapore’s Duke-NUS Medical

LONDON, Oct. 14 (Korea Bizwire) — After almost two years of fight against COVID-19, governments, NGOs, and corporations are now focusing on strategies and solutions to boost population immunity and move onto the next phase – possibly out of the pandemic. Hyris, a global, innovation-based biotechnology company renowned for its inclusive approach to genetic analysis, [...]

UPDATE – UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity

SAN FRANCISCO, Calif. and LONDON, June 7 (Korea Bizwire) – In a study published online in bioRxiv today, scientists at UCSF QBI and the University College, London reported new findings on the viral replication and pathogenesis of the B.1.1.7 U.K. coronavirus strain. In the paper titled, Evolution of Enhanced Innate Immune Evasion by the SARS-CoV-2 B.1.1.7 UK Variant, scientists [...]

AvantGen Receives an Award from the NIH/RADx to Commercialize its Anti-SARS-CoV-2 Nucleocapsid Antibodies for Ultra-high Sensitivity Lateral Flow Assay Development

SAN DIEGO, May 25 (Korea Bizwire) — AvantGen, a San Diego-based biotech, is a leader in the use of yeast display technology for human and rabbit monoclonal antibody discovery and optimization. AvantGen has received an award from the NIH’s RADx Next program to expedite the commercialization of its high affinity rabbit monoclonal antibodies against the nucleocapsid [...]

QuantuMDx Diagnostic Test for SARS-CoV-2 Remains Suitable for the Detection of All Discovered Variants, Including VUI-202012/01

NEWCASTLE UPON TYNE, UK, Dec. 22 (Korea Bizwire) – QuantuMDx Group Limited (“QuantuMDx”), a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new strain of SARS-CoV-2. The UK COVID Genomics Consortium and Public Health [...]

Coronavirus Causes Blood Vessel Inflammation, Immune Inhibition

SEOUL, Aug. 5 (Korea Bizwire) — The novel coronavirus causes blood vessel inflammation and inhibits immune response, tests conducted on primates indicated Wednesday. The infection model research by state-run Korea Research Institute of Bioscience and Biotechnology (KRIBB) showed animals exposed to the SARS-CoV-2 experienced rapid multiplying of the virus in the throat and lungs two [...]

Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China

SHANGHAI, China, July 12 (Korea Bizwire) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today the completion of study subjects enrollment in Phase I trial of SARS-CoV-2 neutralizing monoclonal antibody injection (Product Code: JS016), developed jointly with Institute of Microbiology, Chinese Academy [...]